ERBB2 and cholangiocarcinoma: The highest proportion of HER2 IHC 3+ expression was observed in salivary gland tumors (16.7%, n = 1), followed by esophageal/esophagogastric junction carcinoma (10.3%, n = 3), metastatic breast carcinoma (9.1%, n = 6), epithelial ovarian/fallopian tube carcinomas (6.7%, n = 3), and cholangiocarcinoma (3.6%, n = 2).